UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Fructose-2,6-bisphosphate restores DNA repair activity of PNKP and ameliorates neurodegenerative symptoms in Huntington's disease

Proceedings of the National Academy of Sciences - PNAS, 2024-09, Vol.121 (39), p.e2406308121

2024

Volltextzugriff (PDF)

Combination therapy with Coenzyme Q₁₀ and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's Diseases

Journal of neurochemistry, 2009-06, Vol.109 (5), p.1427-1439

2009

Volltextzugriff (PDF)

Alternative Approaches for the Management of Huntington's Disease: A Narrative Review

Alternative therapies in health and medicine, 2024-02, Vol.30 (2), p.68

2024

Volltextzugriff (PDF)

Long-Term Efficacy and Safety of Deutetrabenazine for Chorea in Huntington’s Disease: Results From the ARC-HD Open-label Study

CNS spectrums, 2021-04, Vol.26 (2), p.164-165

2021

Volltextzugriff (PDF)

Immunomodulation – a disease‐modifying avenue for treatment of Huntington's disease?

Journal of neurochemistry, 2016-06, Vol.137 (5), p.670-672

Bjorkqvist, Maria

2016

Volltextzugriff (PDF)

Translating Therapies for Huntington's Disease from Genetic Animal Models to Clinical Trials

NeuroRx, 2004-07, Vol.1 (3), p.298-306

2004

Volltextzugriff (PDF)

Huntington's disease: a decade beyond gene discovery

Current neurology and neuroscience reports, 2003-07, Vol.3 (4), p.279-284

Hogarth, Penelope

2003

Volltextzugriff (PDF)

Coenzyme Q10 effects in neurological diseases

Physiological research, 2021-12, Vol.70 (Suppl4), p.S683-S714

Rauchová, H

2021

Volltextzugriff (PDF)

Benefit of cognitive behavioral therapy for post-traumatic stress disorder and obsessive-compulsive disorders in Huntington's disease: a case report

Neurocase, 2022-04, Vol.28 (2), p.188-193

2022

Volltextzugriff (PDF)

Current and Possible Future Therapeutic Options for Huntington’s Disease

Journal of Central Nervous System Disease, 2022-04, Vol.14, p.11795735221092517

2022

Volltextzugriff (PDF)

Potential of marine compounds in the treatment of neurodegenerative diseases: a review

Brazilian journal of biology, 2023, Vol.83, p.e266795-9

2023

Volltextzugriff (PDF)

Pathologically activated therapeutics for neuroprotection

Nature reviews. Neuroscience, 2007-10, Vol.8 (10), p.803-808

Lipton, Stuart A

2007

Volltextzugriff (PDF)

Dose-dependent Neuroprotection of VEGF165 in Huntington's Disease Striatum

Molecular therapy, 2013-10, Vol.21 (10), p.1862-1875

2013

Volltextzugriff (PDF)

Hypoxia and the Kynurenine Pathway: Implications and Therapeutic Prospects in Alzheimer’s Disease

Oxidative medicine and cellular longevity, 2021, Vol.2021 (1), p.5522981-5522981

2021

Volltextzugriff (PDF)

Canadian healthcare capacity gaps for disease-modifying treatment in Huntington’s disease: a survey of current practice and modelling of future needs

BMJ open, 2022-06, Vol.12 (6), p.e062740-e062740

2022

Volltextzugriff (PDF)

The Use of the R6 Transgenic Mouse Models of Huntington's Disease in Attempts to Develop Novel Therapeutic Strategies

NeuroRx, 2005-07, Vol.2 (3), p.447-464

2005

Volltextzugriff (PDF)

Using Advances in Neuroimaging to Detect, Understand, and Monitor Disease Progression in Huntington's Disease

NeuroRx, 2004-04, Vol.1 (2), p.263-272

2004

Volltextzugriff (PDF)

[^sup 18^F]D3FSP ([^sup 18^F]D3AV-45) as a PET imaging agent for Abeta plaques in the brain

The Journal of nuclear medicine (1978), 2018-05, Vol.59, p.1031

2018

Volltextzugriff (PDF)

When cytokinin, a plant hormone, meets the adenosine A2A receptor: a novel neuroprotectant and lead for treating neurodegenerative disorders?

PloS one, 2012-06, Vol.7 (6), p.e38865-e38865

2012

Volltextzugriff (PDF)

Fast-forwarding treatment for neurodegenerative disorders

Lancet neurology, 2015-07, Vol.14 (7), p.687-688

Mohammadi, Dara

2015

Volltextzugriff (PDF)

Administration of Repetitive Transcranial Magnetic Stimulation Attenuates Aβ1-42-Induced Alzheimer’s Disease in Mice by Activating β-Catenin Signaling

BioMed research international, 2019-01, Vol.2019 (2019), p.1-8

2019

Volltextzugriff (PDF)

Introducing volume 8 of Neurodegenerative Disease Management

Neurodegenerative disease management, 2018-02, Vol.8 (1), p.1-4

Dormer, Laura

2018

Volltextzugriff (PDF)

News in brief

Lancet neurology, 2014-05, Vol.13 (5), p.452

2014

Volltextzugriff (PDF)

Orphan drugs in development for Huntington's disease: challenges and progress

Orphan drugs, 2015-01, Vol.5, p.1

Burgunder, Jean-Marc

2015

Volltextzugriff (PDF)

S(+)-Propylnorapomorphine Hydrochloride Alters Mutant Huntingtin Aggregation and Membrane Interactions

Pettipas, Gabriella M

2024

Volltextzugriff (PDF)

1 – 25 von 65

Suche als RSS-Feed

Aktive Filter

SprachePortugiesisch

ThemaScience & Technology

ThemaHuntingtons Disease

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(31)

Publikationsform

Sprache

Englisch
(65)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Fructose-2,6-bisphosphate restores DNA repair activity of PNKP and ameliorates neurodegenerative symptoms in Huntington's disease

Combination therapy with Coenzyme Q₁₀ and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's Diseases

Alternative Approaches for the Management of Huntington's Disease: A Narrative Review

Long-Term Efficacy and Safety of Deutetrabenazine for Chorea in Huntington’s Disease: Results From the ARC-HD Open-label Study

Immunomodulation – a disease‐modifying avenue for treatment of Huntington's disease?

Translating Therapies for Huntington's Disease from Genetic Animal Models to Clinical Trials

Huntington's disease: a decade beyond gene discovery

Coenzyme Q10 effects in neurological diseases

Benefit of cognitive behavioral therapy for post-traumatic stress disorder and obsessive-compulsive disorders in Huntington's disease: a case report

Current and Possible Future Therapeutic Options for Huntington’s Disease

Potential of marine compounds in the treatment of neurodegenerative diseases: a review

Pathologically activated therapeutics for neuroprotection

Dose-dependent Neuroprotection of VEGF165 in Huntington's Disease Striatum

Hypoxia and the Kynurenine Pathway: Implications and Therapeutic Prospects in Alzheimer’s Disease

Canadian healthcare capacity gaps for disease-modifying treatment in Huntington’s disease: a survey of current practice and modelling of future needs

The Use of the R6 Transgenic Mouse Models of Huntington's Disease in Attempts to Develop Novel Therapeutic Strategies

Using Advances in Neuroimaging to Detect, Understand, and Monitor Disease Progression in Huntington's Disease

[^sup 18^F]D3FSP ([^sup 18^F]D3AV-45) as a PET imaging agent for Abeta plaques in the brain

When cytokinin, a plant hormone, meets the adenosine A2A receptor: a novel neuroprotectant and lead for treating neurodegenerative disorders?

Fast-forwarding treatment for neurodegenerative disorders

Administration of Repetitive Transcranial Magnetic Stimulation Attenuates Aβ1-42-Induced Alzheimer’s Disease in Mice by Activating β-Catenin Signaling

Introducing volume 8 of Neurodegenerative Disease Management

News in brief

Orphan drugs in development for Huntington's disease: challenges and progress

S(+)-Propylnorapomorphine Hydrochloride Alters Mutant Huntingtin Aggregation and Membrane Interactions

Aktive Filter

Suchergebnisse filtern